Literature DB >> 30536020

Clinical Characteristics and Outcome of Morbidly Obese Bariatric Patients with Concurrent Hepatitis C Viral Infection.

Ming-Lun Han1,2, Wei-Jei Lee3,4, Jung-Chien Chen3, Kong-Han Ser3, Shu-Chun Chen3, Yi-Chih Lee5.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) is an important cause of liver cirrhosis and its complications. The safety and efficacy of bariatric surgery in patients with HCV infection is not clear.
METHODS: Charts were reviewed to identify patients with HCV infection before bariatric surgery. Bariatric surgical patients with non-alcoholic steatohepatitis (NASH) and without NASH (non-NASH) were recruited as comparative groups. Demographic variables, perioperative data, follow-up, and HCV-related parameters were extracted and compared.
RESULTS: Forty-seven bariatric patients between 2000 and 2016 that suffered from HCV infection were identified. The mean age and body mass index (BMI) at baseline were 34.5 ± 9.9 years and 40.4 ± 7.7 kg/m2, respectively. The HCV(+) group was associated with female sex, older age, lower BMI, and waist circumference than both NASH and non-NASH groups. Both HCV(+) and NASH groups had higher liver function tests and incidence of metabolic syndrome than non-NASH group. The HCV(+) group had lower uric acid and albumin level than the NASH group. Early major postoperative complication occurred in 1 (2.1%) patient of the HCV(+) group. At follow-up, the mean BMI decreased to 29.1 ± 7.1 kg/m2 and total weight loss was 25% for the HCV(+) group at 5 years after surgery. The weight loss curves were similar between the HCV(+) group and NASH group. During follow-up, no patients died but one patient with HCV(+) developed flare up of hepatitis after gastric bypass. The mean liver transaminase level remained in normal range for the HCV(+) group.
CONCLUSION: Co-existence of HCV infection does not influence the outcome of bariatric surgery but continued monitoring of the liver function is indicated.

Entities:  

Keywords:  Bariatric surgery; HCV infection; Liver transaminase; Weight loss

Mesh:

Year:  2019        PMID: 30536020     DOI: 10.1007/s11695-018-3615-z

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  28 in total

1.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

Review 2.  The global burden of hepatitis C.

Authors:  Daniel Lavanchy
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828

3.  Bariatric surgery for curing NASH in the morbidly obese?

Authors:  Guillaume Lassailly; Robert Caïazzo; François Pattou; Philippe Mathurin
Journal:  J Hepatol       Date:  2013-01-15       Impact factor: 25.083

Review 4.  Hepatitis C virus induced insulin resistance impairs response to anti viral therapy.

Authors:  Abdel-Rahman El-Zayadi; Mahmoud Anis
Journal:  World J Gastroenterol       Date:  2012-01-21       Impact factor: 5.742

5.  Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study.

Authors:  Eun-Jeong Joo; Yoosoo Chang; Joon-Sup Yeom; Seungho Ryu
Journal:  Hepatology       Date:  2016-12-30       Impact factor: 17.425

6.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

Review 7.  Insulin resistance and steatosis in chronic hepatitis C.

Authors:  Mariana V Machado; Helena Cortez-Pinto
Journal:  Ann Hepatol       Date:  2009       Impact factor: 2.400

8.  Clinical characteristics and outcome of morbidly obese bariatric patients with concurrent hepatitis B viral infection.

Authors:  Wei-Jei Lee; Weu Wang; Yi-Chih Lee; Ming-Te Huang
Journal:  Obes Surg       Date:  2008-05       Impact factor: 4.129

9.  Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease.

Authors:  Gary A Abrams; Sachin S Kunde; Audrey J Lazenby; Ronald H Clements
Journal:  Hepatology       Date:  2004-08       Impact factor: 17.425

Review 10.  Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal.

Authors:  Mariana V Machado; Helena Cortez-Pinto
Journal:  J Hepatol       Date:  2012-11-23       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.